末梢動脈疾患市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed cardiovascular journals, clinical trial repositories, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) and Center for Drug Evaluation and Research (CDER), European Medicines Agency (EMA), National Heart, Lung, and Blood Institute (NHLBI), Centers for Disease Control and Prevention (CDC) Division for Heart Disease and Stroke Prevention, American College of Cardiology (ACC), Society for Vascular Surgery (SVS), European Society of Cardiology (ESC), Vascular Society of Great Britain and Ireland, World Health Organization (WHO) Cardiovascular Disease Programme, ClinicalTrials.gov, PubMed/NCBI, National Center for Health Statistics (NCHS), OECD Health Statistics, and national cardiovascular registries from key markets including the American College of Cardiology's National Cardiovascular Data Registry (NCDR) and the European Society of Cardiology's EURObservational Research Programme.

Interventional procedure volumes, clinical safety and efficacy studies, regulatory approval data for stents and angioplasty devices, epidemiological trends for atherosclerotic disease, and competitive landscape analysis for drug-eluting technologies, atherectomy systems, and antiplatelet/anticoagulant drug categories were all gathered from these sources.

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. Chief Executive Officers, VPs of Regulatory Affairs, heads of Vascular Business Units, and commercial directors from makers of medical devices, cardiovascular pharmaceuticals, and interventional devices were examples of supply-side sources. Procurement leads from tertiary care hospitals, academic medical centers, ambulatory surgery centers, specialized vascular clinics, board-certified interventional cardiologists, vascular surgeons, cath lab medical directors, and hospital pharmacy directors were among the demand-side sources. Primary research confirmed product pipeline timelines for next-generation drug-coated balloons, validated market segmentation across device categories (angioplasty balloons, stents, atherectomy systems) and drug classes (antiplatelets, statins, anticoagulants), and collected information on hospital purchasing dynamics, reimbursement frameworks, and clinical adoption patterns for endovascular procedures.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (33%), Europe (29%), Asia-Pacific (28%), Rest of World (10%)

Revenue mapping and procedure volume analysis tailored to peripheral interventions were used to determine the global market valuation. The following were part of the methodology:

Finding more than 40 major producers and drug developers with expertise in cardiovascular therapies and endovascular devices across North America, Europe, Asia-Pacific, and Latin America

Product mapping across chronic total occlusion (CTO) systems, atherectomy devices, peripheral stents (covered, bare metal, and drug-eluting), angioplasty balloons, and pharmaceutical categories such as glucose-regulating medications, lipid-lowering treatments, and antiplatelet medicines

Peripheral vascular portfolio-specific analysis of reported and estimated yearly revenues, isolating device sales from medication sales

Coverage of producers and researchers who will account for 75–80% of the world market in 2024

Extrapolation utilizing top-down (pharmaceutical sales data and manufacturer revenue validation) and bottom-up (procedure volume × ASP by country for revascularization procedures, adjusted for hospital vs. ASC settings) approaches to determine segment-specific valuations for devices (catheters, plaque modification, hemodynamic flow alteration) and drug classes